Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Apple Turns 50: From Garage Startup to AI Crossroads 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Britain Courts Anthropic Amid US Defense Department Dispute 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
NEW YORK, Dec. 09, 2016 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in following investor conference:
- BMO Prescriptions for Success Healthcare Conference on December 14, 2016 at 1:00 p.m. Eastern Time
Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
For more information about Intercept Pharmaceuticals, please contact: Intercept Pharmaceuticals: Mark Vignola +1-646-747-1000 [email protected] Media inquiries: [email protected] Investor inquiries: [email protected]
